SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis

P Helliwell,O Fitzgerald,T Nurminen,P.J Mease

doi:10.1136/annrheumdis-2014-eular.1654

SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis

P Helliwell, O Fitzgerald + Show 2 more

https://doi.org/10.1136/annrheumdis-2014-eular.1654

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2014
Citations: 1

Affiliation: University College Dublin, NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, UCB Pharma (Germany), Swedish Medical Center, Seattle University, University of Washington

#Composite Psoriatic Disease Activity Index #Psoriatic Arthritis Disease Activity Score + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundSeveral new disease-specific composite disease activity measures have been developed for psoriatic arthritis (PsA).ObjectivesUsing data from a randomized double-blind placebo-controlled trial of certolizumab pegol (CZP) in PsA (RAPID-PsA, NCT01087788) we...

Full Text